Loose bowel motions may be due to an infection (gastroenteritis) but if the symptoms persist for more than 3 weeks then other conditions need to be considered. Sometimes the problem is......

Publications

PUBLISHED ARTICLES:

 

1.         Fraser AG, Henley JW, Ellis-Pegler RB, Benjamin CS, Childs WJ, Harvey VJ. The acquired immunodeficiency syndrome in Auckland in 1985.  New Zealand Medical Journal 1986:99; 485-488

 

2.         Fraser AG, Croxson MS, Ellis-Pegler RB.  Hypercalcaemia and elevated 1,25 dihydroxy-vitamin D3 levels in a patient with multibacillary leprosy and type 1 leprosy reaction.  New Zealand Medical Journal. 1987:100; 86.

 

3.          Fraser AG, Croxson MS, Espiner EA, Synek B.  Adrenocortical carcinoma presenting as primary aldosteronism in a young man.  Australian New Zealand Journal of Medicine 1987:17; 60-62.

 

4.          Ellis-Pegler RB, Beeching NJ, Eales M, Fraser AG, Wells AU.  Fansimef is effective treatment for imported malaria in New Zealand. Australian New Zealand Journal of Medicine 1988:18; 733-734.

 

5.          Browett PJ, Fraser AG, Varcoe AR, Ellis-Pegler RB.  Disseminated tuberculosis complicated by hemophagocytic syndrome.  Australian New Zealand Journal of Medicine 1988:18; 79-80.

6.         Fraser AG. Medicine in rural Kenya - a personal perspective.  New Zealand Medical Journal 1989:102; 15-16.

 

7.         Fraser AG, Hamilton I. Endoscopic palliation of malignant obstructive jaundice.  New Zealand Medical Journal 1989:102; 155-157.

 

8.          Fraser AG,  Parr DH,  Ellis-Pegler RB. The spectrum of systemic candidiasis at Auckland Hospital.  New Zealand Medical Journal 1990:103; 505-507.

 

9.          Fraser AG, Arthur J, Hamilton I.  Intestinal psuedo-obstruction secondary to gastrointestinal amyloidosis responsive to treatment with cisapride.  Digestive Diseases and Sciences 1991:36; 532-535.

 

10.        Fraser AG, Prewett EJ, Sawyer AM, Rosalki SB, Pounder RE. The effect of ranitidine, cimetidine of famotidine on low-dose post-prandial alcohol absorption.  Alimentary Pharmacology and Therapeutics 1991;5:263-272.

 

11.        Prewett EJ, Nwokolo CU, Hudson M, Sawyerr AM, Fraser AG, Pounder RE. The effect of GR 122311X, a bismuth compound with H2-antagonist activity, on 24-hour acidity. Alimentary Pharmacology Therapeutics 1991;5: 481-490.

 

12.       Charkravanty BK, Fraser AG, Hamilton I, Lane M.  A randomised, blinded study in colonic lavage for colonoscopy. Australian and New Zealand Journal of Medicine 1991;21: 769-771.

 

13.       Fraser AG, Debnam ES, Dhillon AP, Pounder RE.  Gastric epithelial cell proliferation after dosing with anti-secretory drugs: the effect of variation in the strain of rat.  European Journal of Gastroenterolgy and Hepatology 1992; 4:651-656 

 

14.       Fraser AG, Nicholson GI.  Duodenal perforation in primary systemic amyloidosis. Gut 1992; 33: 997-9.

 

15.       Fraser AG, Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE. Ranitidine has no effect on post-prandial absorption of alcohol (0.6g/kg) after an evening meal.  European Journal Gastroenterology and Hepatology 1992;4: 43-48.

 

16.       Fraser AG, Debnam ES, Dhillon AP, Pounder RE. Gastric epithelial cell proliferation and histological damage after dosing with hypertonic saline: the effect of variation in the strain of rat. International Journal Experimental Pathology 1992; 73: 241-250

 

17.       Fraser AG, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE. The effect of ranitidine on the post-prandial absorption of a low dose of alcohol. Alimentary Pharmacology Therapeutics 1992; 6: 267-271

18.       Fraser AG, Pounder RE.  H2-antagonists and alcohol. Reply. Aliment Pharmacol Therapeutics 1991;5: 668-670.

 

19.       Fraser AG, Prewett EJ, Pounder RE, Samloff IM. Twenty-four hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is abolished by eradication of the infection. Alimentary Pharmacology Therapeutics 1992, 6:483-394

 

20.       Pounder RE, Fraser AG.  Safety concerns related to the treatment of peptic ulceration. Current opinion in Gastroenterology 1992;7: 894-899.

 

21.       Prewett EJ, Luk YW, Fraser AG, Lam WM, Pounder RE.  Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test. Alimentary Pharmacology and Therapeutics 1992;6: 97-102.

 

22.       Fraser AG, Hudson M, Sawyer AM, Smith M, Rosalki SB, Pounder RE. Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal.  Alimentary Pharmacology and Therapeutics 1992;6: 693-700

 

23.       Fraser AG, Nicholson GI.  Long-term follow-up of dilatation treatment of oesophageal strictures. J Gastroenterology and Hepatology 1992, 7: 520-523

 

24.       Fraser AG, White C, Nicholson G.  Antral vascular ectasia.  N.Z.Med J  1992; 105: 338-9.

25.       Fraser AG, Bickley J, Owen R, Pounder RE.  DNA fingerprints of Helicobacter pylori before and after treatment with omeprazole.  J Clinical Pathology 1992; 45: 1062-1065.

26.       Fraser AG, Lam WM, Luk YW, Sawyerr AM, Hudson M, Smith M, Pounder RE.  The effect of ranitidine bismuth citrate on post-prandial plasma gastrin and plasma pepsinogens. Gut 1993;34: 338-342

27.       Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE. The effect of ranitidine on post-breakfast alcohol absorption. American Journal of Gastroenterology 1993;88: 217-221

 

28.       Fraser AG, Pounder RE, Burroughs AK. Gastric secretion and peptic ulcer in cirrhosis.  Journal of Hepatology 1993; 19: 171-182

 

29.       Bickley J, Owen RJ, Fraser AG, Pounder RE.  Evaluation of the polymerase chain reaction for detecting the urease gene of Helicobacter pylori in gastric biopsies and dental plaque.  Journal of Medical Microbiology 1993; 39: 338-344.

 

30.       Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE.  Effects of ranitidine 150 mg qds on 24-hour intragastric acidity and 24-h plasma gastrin concentration.  Digestive Diseases and Sciences 1994; 39: 91-96.

 

31.       Owen RJ, Bickley J, Hurtado A, Fraser AG and Pounder RE.  Use of rRNA gene profiling and polymerase chain reaction-based restriction length polymorphism analysis of urease genes to monitor Helicobacter pylori infecting patients on triple therapy.  Journal of Clinical Microbiology; 1994; 32: 1203-1210.

 

32.       Fraser AG, Sim R, Sankey EA, Dhillon AP, Pounder RE.  Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharmacol Therap 1994; 8: 167-173.

 

33.       Fraser AG, Lewin JF, Pounder RE.  Gastric persorption of bismuth from ranitidine bismuth citrate.  Aliment Pharmacol Therap 1995:9:447-450.

 

34.       Fraser AG, Rosalki SB, Gamble GG, Pounder RE.  Inter-individual and intra-individual variabililty of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal.  Br J Clin Pharmacol 1995;40:387-392.

 

35.       Fraser AG, Ali MR, McCullough S, Haystead A.  Diagnostic tests for Helicobacter pylori - can they help select patients for endoscopy?  NZ Med J 1996; 109: 95-8.

36.       Fraser AG, Moore L, Ali MR, Hollis B, Little SV.  An audit of low dose triple therapy for eradication of Helicobacter pylori.  NZ Med J 1996; 109; 290-2

37.       Fraser AG, Sawyerr AM,  Hudson M, Smith MS, Pounder RE.  Morning versus evening dosing of lansoprazole 30mg daily on 24‑hour intragastric acidity in healthy subjects. Aliment Pharmacol Therap 1996; 10: 523-527.

38.       Scragg RK, Fraser A, Metcalf PA.  Helicobacter pylori and cardiovascular risk factors in a multicultural workforce.  J Epid Comm Health 1996:50:578-79.

39.       O’Morian C, Dettmer A, Rambow A, von Fritsch E, Fraser AG.   Double-blind multinational, multicentre, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori associated duodenal ulcer.  Helicobacter 1996; 1:130-137.

40.       Fraser AG, Scragg R, Metcalf P, McCullough S, Yeates NJ.  Prevalence of Helicobacter pylori in different ethnic groups in New Zealand children and adults. Aust NZ J Med 1996; 26:646-51 (with editorial).
 

41.       Fraser AG, Moore L, Berry S,  Arroll B.  Eradication treatment for Helicobacter pylori in general practice.  NZ Med J 1996; 109:422-4.

42.       Berry S, Arroll B, Fraser AG, Weller D. Screening for colorectal cancer:  a survey of New Zealand general practitioners.  NZ Med J 1996; 109:447-9.

43.       Perez-Perez GI, Bhat N, Gaensbauer J, Fraser AG, Taylor DN, Kuipers EJ, Zhang L, You WC, Blaser MJ.  Country-specific constancy by age in CagA+ proportion of Helicobacter pylori infections.  Int J of Cancer 1997; 72: 453-56.

44.       Schmid J, Fraser AG, Hollis B, O’Toole P.  Ethnic tropism of DNA fingerprints of Helicobacter pylori.  Infection and Immunity 1997; 65: 3708-12.

45.       Fraser AG, Peng S-L, Jass JR.  Intestinal metaplasia subtypes and Helicobacter pylori infection - a comparison of ethnic groups in New Zealand. 
J Gastro Hepatol 1998; 13: 560-565.

46.       Fraser AG,  McIntosh C, Berry S, Moore L.  Can the urea breath test for H.pylori replace endoscopy for the assessment of dyspepsia in primary care?  N Z J Med 1998; 111; 11-4.

47.       Fraser AG, Schreuder V, Chua L, Moore L.  Follow-up after successful eradication of H.pylori - symptoms and re-infection.  J Gastro Hepatol 1998; 13: 555-59.

48.       Perssons S, Lane MR, Fraser AG.  Long-term follow-up of the management of oesophageal strictures at Auckland Hospital 1990-94.  NZ Med J 1999; 112: 28-29.

49.       Garrigan K, McIntosh C, Fraser AG.  Bleeding peptic ulcers: audit of eradication for H.pylori.  NZ Med J 1999; 112: 178-180.

50.       Fraser AG, Woollard GA.  Gastric juice ascorbic acid is related to Helicobacter pylori infection bit not ethnicity.  J Gastro Hepatol 1999; 14: 1070-73.

51.       Fraser AG, Moore L, Hackett M, Hollis B.  H.pylori treatment and antibiotic susceptibility: results of a five-year audit.   Aust NZ J Med 1999; 29:512-517.

52.       Fraser AG, Morton RP, Gillebrand J.  Presumed laryngo-pharyngeal reflux; investigate or treat.  J Otolaryngology 2000; 114: 441-47.

53.       Fraser AG, Orchard TR, Jewell DP.  The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.  Gut 2002; 50: 485-489.

54.       Fraser AG, Morton D, McGovern D, Travis S, Jewell DP.  The efficacy of methotrexate for maintaining remission in inflammatory bowel disease.  Aliment Pharmacol Therap 2002; 16: 693-697.

55.       Fraser AG, Orchard TR, Robinson EM, Jewell DP.  Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.  Aliment Pharmacol Therap 2002; 16: 1225-1232.

56.       Fraser AG, Warren BF, Chandrapala R, Jewell DP.  Microscopic colitis: a clinical and pathological review.  Scand J Gastroenterol 2002; 11: 1241-45.

57.       Fraser AG, Scragg RK, Cox B, Jackson RT.  Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction.  Int Med J 2003; 33: 267-272.

58.       Fraser AG, Williamson S, Lane MR, Hollis B.  Nurse-led dyspepsia clinic using the urea breath test for H.pylori.  NZ Med J 2003; 116: 479-83.

59.       Fraser AG.    Helicobacter pylori: a historical perspective 1983-2003.  NZ Med J; 2004; 117: 1194

60.       Fraser AG, Kandiel A, Korelitz  BI,  Brensinger C,  Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 2005; 54, 1121-1125
 

61.       Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WGH, Krissansen GW.  Polymorphisms of CARD15/NOD2 and CD14 genes in New Zealand Crohn's disease patients. Immunology and Cell Biology 2005; 83: 498-503.
 

62.       Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Abbott WGH, Krissansen GW Peroxisome proliferator-activated receptor-g gene polymorphisms and Crohn's disease. Int J Colorectal Dis 2007; 22:453-4.

63.       Leung E, Hong J, Fraser AG, et al.  Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn’s diseas in a New Zealand caucasian cohort.  Immunoly and Cell Biology 2006; 84: 233-6.

64.       Leung E, Hong J, Fraser AG, Merriman T, Krissansen G.  PPAR-gamma and Crohn’s disease.  Gastroenterology 2005; 128:351-60.  Author reply Gastroenterology 2006; 130:2249-50.

65.       Leung E, Hong J, Fraser AG, Krissansen GW.  Spicing of NOD2 (CARD15) RNA transcripts.  Molecular Immunology 2007; 8:995-6.

66.       Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Krissansen GW.  Colony-stimulating factor-1 receptor gene polymorphisms.  Int J Colorect Dis 2007; 8: 995-6.

67.       Leung E. Hong J. Fraser AG. Merriman TR. Vishnu P. Krissansen GW. Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New Zealand Caucasian cohort. Immunology & Cell Biology 2006; 84:233-6.
 

68.       Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007: 22: 1760-1766.
 

69.       Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. Polymorphisms in NFKBIA and ICAM-1 genes in New Zealand Caucasian Crohn's disease patients.  J Gastroenterol  Hepatol 2007; 22: 1666-1670.

70.       MORGAN, A.R.,  HAN, D.Y.,  TRIGGS, C.M.,  LAM, W.J.,  FRASER, A.G.,  BARCLAY, M.,  GEARRY, R.,  FERGUSON, L.R.  'Genetic variation in the matrix metalloproteinases is associated with inflammatory bowel disease', IPODD annual meeting, Prague, 15-18 July, 2009


71.       HAN, D.Y.,  FRASER, A.G.,  GRAINGER, P.A.,  FERGUSON, L.R.  'Environmental factors in the development of chronic inflammation: A case-control study on risk factors for Crohn,s disease within New Zealand', Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, Sep 12, p-, 2009, doi:10.1016/j.mrfmmm.2009.09.002


72.       HONG, J.,  LEUNG, E.,  FRASER, A.G.,  MERRIMAN, T.R.,  VISHNU, P.,  KRISSANSEN, G.W.  'IL4, IL10, IL16, and TNF polymorphisms in New Zealand Caucasian Crohn's disease patients.', International Journal of Colorectal Disease, 23, (3), p335-337, 2008

 


Reviews, book chapters

 

1.         Fraser AG.  Antiulcer drugs. New Ethicals February 1992 (revised and reprinted March 1994)

 

2.         Pounder RE, Fraser AG.  Duodenal ulceration. Recent advances in Gastroenterolgy . 9th edition 1992,  pp105-118.

 

3.         Fraser AG. Gastro-oesophageal reflux and laryngeal symptoms. Aliment Pharmacol Therap 1994; 8: 265-272.

 

4.         Pounder RE, Fraser AG. Peptic ulceration. Diagnosis, medical management and complications.  In  Bockus Gastroenterology. Ed. Haubrick, Schaffner, Berk, 5th edition 1994  pp 749-790.

 

5.         Pounder RE, Fraser AG. Gastric acid secretion: measurement in health and disease. Balliere's Clinical Gastroenterology,  March 1993, Vol 7, No 1, pp 55-80.

 

6.         Richards J, Charlesworth P, Fraser A.  Therapeutic Forum - Reflux oesophagitis.  Patient Management   April 1994 (reprinted 1997).

 

7.         Fraser AG,  Rose T.  Nausea and vomiting.  Patient Management, November 1994 (reprinted 1997).

 

8.         Rose T, Fraser AG.  Dysphagia.  Patient Management,  February1995.

 

9.         Rose T, Fraser AG.  Hepatitis A to E.  Patient Management,  October1995

 

10.       Fraser AG.  Dyspepsia.  Patient Management,  December 1995 .

 

11.       Rose T, Fraser AG.  Chronic diarrhoea. - a clinical approach.  Patient Management  Dec 1996

 

12.       Fraser AG.  Editorial.  How helpful are tests for Helicobacter pylori in general practice.  New Ethicals  Feb1997, pp 9-16.

 

13.       Fraser AG.  Review.  The effect of alcohol on the pharmacokinetics of drug therapy.  Clin Pharmacokinetics 1997; 33: 79-90.

 

14.       Fraser AG.  Is there an interaction between H2-antagonists and alcohol?  Drug Metabolism and Drug Interactions  1998; 14: 123-146.

 

15.       Fraser AG.  Microscopic colitis.  Medicine International 2003; 31(2): 82-3.

 

16.       Fraser AG.   Interpretation of liver enzyme tests: a rapid guide.  NZ Family Physician 2002; 29 (2):  117-120.

 

17.       Fraser AG.  Methotrexate:  first or second-line immunomodulator?  Eur J Gastroenterol Hepatol

 

18.       Fraser AG.  Inflammatory bowel disease.  NZ Family Physician. 2003; 30: 425-30.

 

19.       Fraser AG.  Coeliac disease.  NZ Family Physician 2004; 31:161-64

 

20.       Fraser AG.  Fatty liver.  NZ Family Physician 2004; 31: 399-401

designed and developed by QT Web